Top

Current Bladder Dysfunction Reports

Published in:

01-06-2017 | BPH-Related Voiding Dysfunction (R Lee, Section Editor)

Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms

Authors: Grace E. Kohn, Taylor P. Kohn, Ranjith Ramasamy

Published in: Current Bladder Dysfunction Reports | Issue 2/2017

Abstract

Purpose of Review

While early studies suggested that testosterone replacement therapy would enlarge the prostate and worsen lower urinary tract symptoms, this review seeks to examine the combined evidence of observational studies, randomized control trials, and meta-analyses published on the topic to determine if testosterone replacement therapy worsens lower urinary tract symptoms in hypogonadal men.

Recent Findings

The combined evidence of 15 randomized control trials and 2 meta-analyses has demonstrated emphatically that testosterone replacement therapy has no effect on lower urinary tract symptoms in hypogonadal men with mild and moderate symptoms.

Summary

No randomized control trial has sufficiently examined the effect of testosterone replacement therapy in men with severe lower urinary tract symptoms. While a few observational studies have seen no effect when hypogonadal men with severe lower urinary tract symptoms are treated with testosterone replacement therapy, future randomized controlled trials specifically studying the effect of testosterone on men with severe lower urinary tract symptoms are warranted. In summary, clinicians should rest assured that testosterone does not worsen lower urinary tract symptoms in hypogonadal men with mild or moderate lower urinary tract symptoms.

Behre HM, Tammela TL, Arver S, Tolra JR, Bonifacio V, Lamche M, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. The aging male: the official journal of the International Society for the Study of the Aging Male. 2012;15(4):198–207. doi:10.3109/13685538.2012.699562.CrossRef

Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589–98. doi:10.1210/jcem.87.2.8201.CrossRefPubMed

Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–31. doi:10.1210/jcem.86.2.7219.CrossRefPubMed

Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3469–78. doi:10.1210/jcem.84.10.6078.PubMed

Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58(6):1134–43. doi:10.1111/j.1532-5415.2010.02865.x.CrossRefPubMedPubMedCentral

Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2670–7. doi:10.1210/jcem.85.8.6731.PubMed

Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, et al. Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. The Journal of Clinical Endocrinology & Metabolism. 1996;81(10):3578–83.

Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men 1. The Journal of Clinical Endocrinology & Metabolism. 2000;85(8):2839–53.

Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology. 2006;68(4):804–9. doi:10.1016/j.urology.2006.04.019.CrossRefPubMed

10.

Jones C, Hill J, Chapple C. Management of lower urinary tract symptoms in men: summary of NICE guidance. BMJ (Clinical research ed). 2010;340:c2354. doi:10.1136/bmj.c2354.CrossRef

11.

Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549–57. discussion 64PubMed

12.

Huggins C, Stevens Jr RE, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43(2):209–23. doi:10.1001/archsurg.1941.01210140043004.CrossRef

13.

•• Cui Y, Zhang Y. The effect of androgen-replacement therapy on prostate growth: a systematic review and meta-analysis. Eur Urol. 2013;64(5):811–22. doi:10.1016/j.eururo.2013.03.042. This meta-analysis demonstrates that prostate size does not change in hypogonadal men undergoing androgen replacement therapy.

14.

Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. The aging male : the official journal of the International Society for the Study of the Aging Male. 2011;14(1):53–8. doi:10.3109/13685538.2010.518178.CrossRef

15.

• Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314(6):570–81. doi:10.1001/jama.2015.8881. In this recently published randomized control trial of 248 hypogondal men, the authors demonstrate no clinically or statistically significant increase in lower urinary tract symptoms after 3 years of testosterone replacement therapy.

16.

Chiang HS, Hwang TI, Hsui YS, Lin YC, Chen HE, Chen GC, et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. Int J Impot Res. 2007;19(4):411–7. doi:10.1038/sj.ijir.3901562.CrossRefPubMed

17.

Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol. 2010;73(5):602–12. doi:10.1111/j.1365-2265.2010.03845.x.CrossRef

18.

Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001;56(5):M266–72.CrossRefPubMed

19.

•• Kohn TP, Mata DA, Ramasamy R, Lipshultz LI. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol. 2016; doi:10.1016/j.eururo.2016.01.043. This meta-analysis demonstrates that lower urinary tract symptoms are not worsened in hypogonadal men undergoing testosterone replacement therapy.

20.

Konaka H, Sugimoto K, Orikasa H, Iwamoto T, Takamura T, Takeda Y, et al. Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: a multicenter randomized controlled trial in Japan (EARTH Study). Asian journal of andrology. 2015; doi:10.4103/1008-682x.148720.PubMedCentral

21.

Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351–61. doi:10.1001/jama.296.19.2351.CrossRefPubMed

22.

Meuleman EJ, Legros JJ, Bouloux PM, Johnson-Levonas AO, Kaspers MJ, Elbers JM, et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. The aging male : the official journal of the International Society for the Study of the Aging Male. 2015;18(3):157–63. doi:10.3109/13685538.2015.1032925.

23.

Paduch DA, Polzer PK, Ni X, Basaria S. Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. J Clin Endocrinol Metab. 2015;100(8):2956–62. doi:10.1210/jc.2014-4434.

24.

Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50. doi:10.1210/jc.2009-1251.CrossRefPubMed

25.

Tan WS, Low WY, Ng CJ, Tan WK, Tong SF, Ho C, et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU Int. 2013;111(7):1130–40. doi:10.1111/bju.12037.CrossRefPubMed

26.

Tammela T. Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging. 1997;10(5):349–66.CrossRefPubMed

27.

Peehl DM. Basic science of hormonal therapy for prostate cancer. Reviews in urology. 2001;3(Suppl 3):S15–22.PubMedPubMedCentral

28.

Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59. doi:10.1210/jc.2009-2354.CrossRefPubMed

29.

Holmäng S, Mårin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate. 1993;23(2):99–106. doi:10.1002/pros.2990230203.CrossRefPubMed

30.

Brock G, Heiselman D, Maggi M, Kim SW, Rodriguez Vallejo JM, Behre HM, et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. J Urol. 2016;195(3):699–705. doi:10.1016/j.juro.2015.10.083.CrossRefPubMed

31.

Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Jama. 2008;299:39.

32.

Pearl JA, Berhanu D, François N, Masson P, Zargaroff S, Cashy J, et al. Testosterone supplementation does not worsen lower urinary tract symptoms. J Urol. 2013;190(5):1828–33. doi:10.1016/j.juro.2013.05.111.CrossRefPubMed

33.

Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55(2):310–20. doi:10.1016/j.eururo.2008.09.024.CrossRefPubMed

Title: Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms
Authors: Grace E. Kohn
Taylor P. Kohn
Ranjith Ramasamy
Publication date: 01-06-2017
Publisher: Springer US
Published in: Current Bladder Dysfunction Reports / Issue 2/2017
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-017-0419-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2017

Meditate Temporary Implantable Nitinol Device

Accurate Estimation of Prostate Size in the Evaluation of Nocturia

Urinary Diversion for Incontinence and Voiding Dysfunction in Cancer Survivors: a Critical Review of the Literature

Neuromodulation in the Treatment of Voiding Dysfunction and Fecal Incontinence in Male and Female Cancer Survivors

The Male Transobturator Sling for Stress Incontinence After the Treatment of Prostate Cancer

Outlet Procedures in Female Cancer Survivors for the Treatment of Stress Incontinence: Differences in Indications, Technique, and Outcome for the Cancer Survivor